Key clinical point: A dose of 120 mg galcanezumab subcutaneously safely and effectively reduces headache frequency, intensity, and duration in patients with episodic and chronic migraine and previous unsuccessful preventive treatments.
Major finding: The 6-month galcanezumab treatment led to a significant decrease in the headache attack frequency ( −14.19 headache days/month; P< .001), headache attack pain intensity (numerical rating scale score −2.74; P< .001), and headache attack duration ( −6.65 hours; P< .001).
Study details: The data come from an observational, prospective study including 43 patients with episodic high frequency and chronic migraine and unsuccessful treatment with ≥3 preventive medication classes who received monthly 120 mg galcanezumab subcutaneously.
Disclosures: This study received no specific funding. Some authors declared receiving speaker honoraria and travel funding from various sources and serving as associate editors of neurology journals such as European Journal of Neurology .
Source: Silvestro M et al. Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: A real-world experience.J Headache Pain. 2022;23:69(Jun 13. Doi: 10.1186/s10194-022-01436-6